AstraZeneca PLC

AZN remains in a Stage 3 downtrend with lower highs and lows under declining EMAs. Supply dominates, and recent rallies are being rejected at resistance. We favor initiating bearish engagements now, selling into the pullback at dynamic EMA resistance.

• ↑Revenue rose 6% to $25.3B, core EPS up 11%, oncology +15%.
• ↑25 Phase III readouts in next 18 months underpin future launches.
• ↓Farciga and Brilinta facing generic entry, risking material revenue declines.